Discovery of VU6024578/BI02982816: An mGlu 1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c02554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Carson W Reed und 21 weiteren Autor:innen. Beteiligte Einrichtung: Warren Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37067, Unites States. Hauptthemen laut MEDLINE: Receptors, Metabotropic Glutamate, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NICHD NIH HHS, NIMH NIH HHS, NIH HHS.
Abstract (Originalsprache)
Herein, we report progress toward a metabotropic glutamate receptor subtype 1 (mGlu1) positive allosteric modulator (PAM) clinical candidate and the discovery of VU6024578/BI02982816. From a weak high-throughput screening hit (VU0538160, EC50 > 10 μM, 71% Glumax), optimization efforts improved functional potency over 185-fold to deliver the selective (inactive on mGlu2-5,7,8) and CNS penetrant (rat Kp = 0.99, Kp,uu = 0.82; MDCK-MDR1 ER = 1.7, Papp = 73 × 10-6 cm/s) mGlu1 PAM (VU6024578/BI02982816, EC50 = 54 nM, 83% Glumax). An excellent rat pharmacokinetic profile allowed the evaluation of VU6024578/BI02982816 in both amphetamine-induced hyperlocomotion (minimum effective dose (MED) = 3 mg/kg, p.o.) and MK-801 induced disruptions of novel object recognition (MED = 10 mg/kg p.o.), thus providing efficacy in preclinical models of psychosis and cognition. However, unanticipated AEs in dog prevented further consideration as a candidate. Thus, VU6024578/BI02982816 can serve as a best-in-class in vivo rodent tool to study selective mGlu1 activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Warren Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37067, Unites States.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach 88397, Germany.
ORCID-Profile: Craig W Lindsley
Förderung
- NICHD NIH HHS
- NIMH NIH HHS
- NIH HHS
- National Institute of Mental Health
- Boehringer Ingelheim
Zitieren
APA
Reed, C. W., Kalbfleisch, J. F., Turkett, J. A., Trombley, T. A., Nastase, A. F., Spearing, P. K., Haymer, D. H., Sarwar, M. M., Quitalig, M., Dickerson, J. W., Blobaum, A. L., Boutaud, O., Voehringer, P., Schuelert, N., Cho, H. P., Niswender, C. M., Rook, J. M., Priepke, H., Ursu, D., …, & Lindsley, C. W. (2024). Discovery of VU6024578/BI02982816: An mGlu 1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02554
Vancouver
Reed CW, Kalbfleisch JF, Turkett JA, Trombley TA, Nastase AF, Spearing PK, et al. Discovery of VU6024578/BI02982816: An mGlu 1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c02554
BibTeX
@article{Reed2024,
author = {Reed, Carson W and Kalbfleisch, Jacob F and Turkett, Jeremy A and Trombley, Trevor A and Nastase, Anthony F and Spearing, Paul K and Haymer, Daniel H and Sarwar, Mohammad Moshin and Quitalig, Marc and Dickerson, Jonathan W and Blobaum, Annie L and Boutaud, Olivier and Voehringer, Patrizia and Schuelert, Niklas and Cho, Hyekyung P and Niswender, Colleen M and Rook, Jerri M and Priepke, Henning and Ursu, Daniel and Conn, P Jeffrey and Melancon, Bruce J and Lindsley, Craig W},
title = {Discovery of VU6024578/BI02982816: An mGlu 1 Positive Allosteric Modulator with Efficacy in Preclinical Antipsychotic and Cognition Models},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c02554}
}
EUVIMED